This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Availability, need for, and use of work accommodations and benefits: are they related to employment outcomes in people with arthritis?
Arthritis care & research · 2015 · senior author
Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival.
Gynecologic oncology · 2013
Measures of disability: Arthritis Impact Measurement Scales 2 (AIMS2), Arthritis Impact Measurement Scales 2-Short Form (AIMS2-SF), The Organization for Economic Cooperation and Development (OECD) Long-Term Disability (LTD) Questionnaire, EQ-5D, World Health Organization Disability Assessment Schedule II (WHODASII), Late-Life Function and Disability Instrument (LLFDI), and Late-Life Function and Disability Instrument-Abbreviated Version (LLFDI-Abbreviated).
Arthritis care & research · 2011
Latest funding
- $1,082,474
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
CIHR · 2020 · Principal investigator
3 publications.
Availability, need for, and use of work accommodations and benefits: are they related to employment outcomes in people with arthritis?
Gignac MA, Cao X, McAlpine J
Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival.
Bernard B, Clarke BA, Malowany JI, McAlpine J, Lee CH, Atenafu EG, Ferguson S, Mackay H
Measures of disability: Arthritis Impact Measurement Scales 2 (AIMS2), Arthritis Impact Measurement Scales 2-Short Form (AIMS2-SF), The Organization for Economic Cooperation and Development (OECD) Long-Term Disability (LTD) Questionnaire, EQ-5D, World Health Organization Disability Assessment Schedule II (WHODASII), Late-Life Function and Disability Instrument (LLFDI), and Late-Life Function and Disability Instrument-Abbreviated Version (LLFDI-Abbreviated).
Gignac MA, Cao X, Mcalpine J, Badley EM
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
Principal investigators: Han, Kathy; Mcalpine, Jessica N
Keywords: Clinical Trial; De-Escalation Therapy; Decisional Conflict; Endometrial Cancer; Molecular Biomarker; P53/Tp53; Personalized Cancer Treatment; Pole; Quality Of Life; Translational Research
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.